neovascular age-related macular degeneration
Ophthalmology · 2022–2022
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| faricimab Treatment of neovascular age-related macular degeneration (nAMD), specifically subfoveal choroidal neovascularisation due to AMD. | May 2022 | Recommended with restriction | input received Macular Disease Foundation Australia |
Who spoke
Macular Disease Foundation Australia
What the PBS pays
$134M in government benefit over 2024–25, across 127,305 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| faricimab | $134.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.